3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
17
Phase 1
10
Phase 3
4
Phase NA
1
Phase EARLY_PHASE1
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Lymphoma
6
Leukemia
6
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, Non-Hodgkin
4
Recurrence
3
Sezary Syndrome
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Myelodysplastic Syndromes
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Follicular
2
Leukemia, T-Cell
2
Leukemia, Myeloid, Acute
2
Leukemia, Biphenotypic, Acute
2
Congenital Abnormalities
2
Waldenstrom Macroglobulinemia
1
Thrombocythemia, Essential
1
Testicular Neoplasms
1
Testicular Germ Cell Tumor
1
Teratoma
1
Small Cell Lung Carcinoma
1
Seminoma
1
Sarcoma, Ewing
1
Retinoblastoma
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Neuroblastoma
1
Neoplasms
1
Myeloproliferative Disorders
1
Interventions
Lomustine
2
Gefitinib
2
Carboplatin
2
trofosfamide
1
tozuleristide
1
entrectinib
1
Vincristine
1
Thiotepa
1
Temozolomide
1
Sunitinib
1
Radiotherapy
1
Methylprednisolone
1
Maintenance Chemotherapy
1
Magnetic Resonance Spectroscopy
1
Induction Chemotherapy
1
Etoposide
1
Erlotinib Hydrochloride
1
Diploidy
1
Dexamethasone
1
Cyclophosphamide
1
Cisplatin
1
Cholecalciferol
1
Bevacizumab
1
Adrenal Cortex Hormones
1
AZD3759
1
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Brain Neoplasms
×
Etoposide
×
Clear all
NCT00749723
2018-07-20
HIT-REZ-2005
University Hospital, Bonn
Phase 2/3
Completed
174 enrolled